Retrospective Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Mar 28, 2021; 27(12): 1194-1212
Published online Mar 28, 2021. doi: 10.3748/wjg.v27.i12.1194
Table 1 Patients’ characteristics in this study
Characteristics

Age (yr, mean ± SD)16-82 (38.7 ± 16.7)
SexMale 29, female 26
Disease duration from diagnosis (mo, mean ± SD)1-384 (59.4 ± 78.8)
Disease extent
Left-sided colitis12
Pancolitis43
Disease refractory type
Steroid-dependent33
Steroid-refractory21
Refusal of steroids1
Clinical type
One-attack4
Relapsing-remitting50
Chronic continuous1
Mean CAI (mean ± SE) (pre first course of CAP)9.0 ± 0.62
Mean DAI (mean ± SE) (pre first course of CAP)11.3 ± 0.55
Medication (pre first course of CAP)
PSL (oral)Yes 54, no 1
5-ASAYes 52, no 3
ThiopurinesYes 12, no 43
TNF-α antibodiesYes 1 (adalimumab), no 54
Vedolizumab, tofacitinib, tacrolimus, ustekinumabYes 0, no 55
Dose of PSL at the start of CAP (mean ± SD)0-60 mg (33.4 ± 19.2)
Type of CAPGMA 38, LCAP 17
Observation period after the first course of CAP (mo, mean ± SD)18-193 (81.5 ± 47.3)
Table 2 Laboratory data obtained (mean ± SE) before and after cytapheresis

Before CAP
After CAP
P value
CRP (mg/dL)1.795 ± 0.7210.312 ± 0.130P = 0.0396
Albumin (g/dL)3.579 ± 0.1393.911 ± 0.117P = 0.0358
Neutrophil count (μL)6826 ± 5615475 ± 456P = 0.0124
Monocyte count (μL)588 ± 73425 ± 46P = 0.0626
Table 3 Previous studies examining the efficacy of cytapheresis in refractory ulcerative colitis
Ref.
Refractory type
Number of patients
Evaluation items1
Rate of remission (evaluation time)
Rate of steroid- free remission (evaluation time)
Naganuma et al[44] (2004)SR10InductionSevere 20%, moderate 70%
Giampaolo et al[45] (2006)SR8Induction, sustained remission100%100%, 12.5% (12 mo)
Ricart et al[46] (2007)SD20Induction, sustained remission42.1% (17 wk)36.8% (17 wk), 85.7% (12 mo)
Cabriada et al[47] (2010)SD18Induction, sustained remission55% (1 mo), 75% (12 mo)
Cabriada et al[48] (2012)SD142Induction, sustained remission37% (1 mo), 51%2 (12 mo)
Sacco et al[49] (2013)SD + SR83 (SD 55, SR 28)Induction, sustained remission71%, 48% (12 mo)
Yokoyama et al[43] (2014)SD + SR401 (SD 229, SR 172)InductionSD: 64.6% (2 wk), SR: 70.9 (2 wk)
Dignass et al[50] (2016)SD86Induction39.3% (12 wk)22.6% (12 wk)
Imperiali et al[51] (2017)SD33Induction36% (12 mo)
Dignass et al[52] (2018)SD95Induction34.0% (24 wk), 33.0% (48 wk)19.2% (24 wk), 19.2% (48 wk)
Domènech et al[53] (2018)SD63Induction13% (24 wk)
Present studySD + SR55 (SD 33, SR 21)Induction, sustained remissionSD: 69.7% (4 wk), SR: 66.7% (4 wk)SD: 42.4% (4 wk) SR: 47.6% (4 wk); SD: 69.2% (12 mo), SR: 63.6% (12mo)